capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
pharma · Breast Neoplasms · Radiation Injuries
Sun Yat-sen Memorial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen Memorial drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Guangzhou, CN HQ
32 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Guangzhou, CN
- Employees
- 32
- Programs
- 7
- Drugs
- 16
- Patents
- 0
Sun Yat-sen Memorial pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sun Yat-sen Memorial drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records.
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records.
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
neratinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sun Yat-sen Memorial's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
niraparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sun Yat-sen Memorial's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pertuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records.
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records.
-
Development asset linked to Sun Yat-sen Memorial in public FDA and regional records.
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor